Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-antigen-positive chronic hepatitis B with α-interferon plus a nucleos(t)ide analog
Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-antigen-positive chronic hepatitis B with α-interferon plus a nucleos(t)ide analog
复制标题
DOI：
10.1111/j.1440-1746.2011.06970.x
复制
发表时间：
2012-03-01
影响因子：
4.1
通讯作者：
Wu, Hao
中科院分区：
文献类型：
--
作者：
Chen, Xinyue;Cao, Zhenhuan;Wu, Hao
Background and Aim: Hepatitis B surface antigen (HBsAg) clearance is the closest cure outcome in hepatitis B. The goal of this study was to investigate clinical features in chronic hepatitis B patients achieving seroconversion of HBsAg after treatment with a-interferon (IFN-alpha) and a nucleos(t)ide analog.Methods: This retrospective study enrolled 38 chronic hepatitis B patients treated with IFN-alpha plus a nucleos(t) ide analog who achieved HBsAg seroconversion during the period from June 2001 to May 2009. Clinical and laboratory data of the patients were collected before and after treatment every 3 months. All patients with HBsAg seroconversion in this study were followed up for at least 12 months post-treatment.Results: A total of 38 out of 142 patients achieved HBsAg seroconversion after treatment with IFN-a and a nucleos(t) tide analog for a prolonged period of time (medium 31 months). The median time to hepatitis B e antigen seroconversion and to HBsAg seroconversion was 19.5 months (range 3-60 months) and 25.5 months (range 9-63 months), respectively. Thirty-six patients (95%) sustained HBsAg seroconversion during the post-treatment follow up. Three different HBsAg response patterns were observed with classical model accounting for 57.9% (22/38 cases), simultaneous transition mode accounting for 23.7% (9/38 cases), and HBsAg prior transition model accounting for 18.4% (7/38 cases).Conclusions: Extended treatment with IFN-a in combination with a nucleos(t) ide analog in patients with hepatitis-B-e-antigen-positive appears to be a promising approach for achieving a high rate of HBsAg clearance-the closest outcome to cure.
